ImmunityBio
Tracked across 9 events · 314 articles · First seen Apr 01, 2026 · Last active Aug 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: ImmunityBio is the defendant in multiple securities class action lawsuits due to alleged misleading statements about its drug Anktiva, which caused its stock price to fall significantly. The company faces investigations and potential financial penalties.
Apr 02, 2026 · 132 articles
Business
Impact: ImmunityBio is subject to a class action lawsuit due to allegations that its capabilities were materially overstated, resulting in misleading statements to investors.
May 18, 2026 · 20 articles
Tech
Researchers are developing vaccines to prevent colon cancer in people with Lynch syndrome, an inherited condition that greatly increases the risk of colorectal and other cancers. At least three experimental vaccines are in development: Nouscom's…
Impact: ImmunityBio's Tri-Ad5 vaccine is in a larger trial, and positive results could significantly boost the company's pipeline and valuation.
Aug 06, 2026 · 20 articles
Tech
Impact: ImmunityBio developed N-803 (Anktiva), which was used in combination with MiNK Therapeutics' Agent 797, potentially increasing the visibility and market for their product.
May 20, 2026 · 9 articles
65
ImmunityBio conducting trialLynch syndrome colon...
Patrick Soon-Shiong
founder, chairman
↔
ImmunityBio
Patrick Soon-Shiong is the founder, executive chairman, and global chief scienti
ERGEN INTELLIGENCE
Track ImmunityBio live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard